Patient demographics after propensity score matching
| CONTROL | TXA+ | P value | |
| Age (years)* | 51.4 (21.4) | 49.8 (20.9) | 0.43 |
| BMI† | 28.7 (23.95, 34.05) | 28.6 (25.3, 34.15) | 0.45 |
| Gender (% male) | 53.50% | 57% | 0.55 |
| Mechanism (% penetrating) | 3.50% | 1.50% | 0.34 |
| ISS† | 10 (9, 22) | 12.5 (9, 22) | 0.16 |
| Head AIS* | 0.75 (1.2) | 0.79 (1.4) | 0.78 |
| Chest AIS* | 1.2 (1.6) | 1.4 (1.7) | 0.29 |
| Abdomen AIS* | 0.5 (1.1) | 0.9 (1.3) | <0.01 |
| Extremity AIS* | 2.49 (0.9) | 2.64 (1.01) | 0.12 |
| TXA given in first 24 hours | 2% | 57% | <0.01 |
| Massive transfusion (%) | 2% | 4.50% | 0.26 |
| Ortho OR within 6 hours of admit | 6% | 11% | 0.06 |
| Time to definitive ortho repair† (hours) | 16.2 (11.1, 23.8) | 21.8 (13.1, 46.7) | <0.01 |
| Damage control surgery (%) | 10% | 11.62% | 0.63 |
| DVT ppx type | |||
| Enoxaparin | 49% | 52% | 0.23 |
| Enoxaparin pre, rivaroxaban post | 14% | 19% | |
| Heparin subq | 3% | 3% | |
| Rivaroxaban | 24% | 24% | |
| Antiplatelet only | 1% | 1% | |
| Therapeutic anticoagulation | 5% | 2% | |
| None | 5% | 1% | |
| Missed doses of DVT ppx† | 2.8 (2.3) | 3.3 (3.4) | 0.09 |
| DVT ppx held for ortho OR | 91% | 92% | 0.724 |
*Mean with SD.
†Median with IQR.
AIS, abbreviated injury score ; BMI, body mass index; DVT ppx, deep vein thrombosis prophylaxis; ISS, Injury Severity Score ; OR, operating room; post, postoperative; pre, preoperative; subq, subcutaneous; TXA, tranexamic acid.